Advanced Adrenocortical Carcinoma (ACC): a Review with Focus on Second-Line Therapies.

ABSTRACT: Advanced adrenocortical cancer (ACC) is a rare, highly aggressive malignancy, which typically has a poor prognosis. In advanced ACC, the overall trend is toward a short PFS interval following first-line systemic therapy, highlighting a clear need for improved second-/third-line treatment strategies. We conducted a review of the literature and relevant scientific guidelines related to systemic therapy for advanced ACC. Public indexes including PubMed/MEDLINE were searched. Treatment selection in the second-line setting is based on small phase 2 trials, case reports, and pre-clinical evidence. The best data available for initial second-line therapy selection supports the use of gemcitabine and capecitabine (G + C) or streptozotocin (S), both with or without mitotane. G + C is becoming increa

SUBMITTER: Ardolino L 

PROVIDER: S-EPMC10355245 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature